Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening

Hepatology

Volumn 56, Issue 2, 2012, Pages 455-463

  Vujosevic, Stela ^a   Tempesta, Diego ^b   Noventa, Franco ^c   Midena, Edoardo ^a,c   Sebastiani, Giada ^b,d  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b OSPEDALE DELL'ANGELO   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; THYROTROPIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRYOGLOBULINEMIA; EYE EXAMINATION; FEMALE; HAZARD RATIO; HEPATITIS C; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA HEMORRHAGE; RETINOPATHY; TREATMENT DURATION; VISUAL ACUITY;

ADULT; ANTIVIRAL AGENTS; DIABETIC RETINOPATHY; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DRUG MONITORING; FEMALE; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION; HYPERTENSIVE RETINOPATHY; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MASS SCREENING; METABOLIC SYNDROME X; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RISK FACTORS;

EID: 84864370893     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25654     Document Type: Article

References (24)

1. Craxi A. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
2. Ferenci P. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future. Expert Opin Drug Saf 2011; 10: 529-544.
3. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. HEPATOLOGY 2011; 54: 1433-1444.
4. Okuse C, Yotsuyanagi H, Nagase Y, Kobayashi Y, Yasuda K, Koike K, et al. Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol 2006; 12: 3756-3759.
5. Schulman JA, Liang C, Kooragayala LM, King J. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003; 110: 437-442.
6. Saito H, Ebinuma H, Nagata H, Inagaki Y, Saito Y, Wakabayashi K, et al. Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C. Liver 2001; 21: 192-197.
7. Panetta JD, Gilani N. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. Aliment Pharmacol Ther 2009; 30: 597-602.
8. Cuthbertson FM, Davies M, McKibbin M. Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol 2004; 88: 1518-1520.
9. Malik NN, Sheth HG, Ackerman N, Davies N, Mitchell SM. A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK. Br J Ophthalmol 2008; 92: 256-258.
10. Chisholm JA, Williams G, Spence E, Parks S, Keating D, Gavin M, et al. Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. Aliment Pharmacol Ther 2005; 21: 723-732.
11. Sene D, Touitou V, Bodaghi B, Saadoun D, Perlemuter G, Cassoux N, et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007; 13: 3137-3140.
12. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062.
13. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713.
14. Pemu PI, Ofili E. Hypertension in women. Part II. J Clin Hypertens 2008; 10: 497-500.
15. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011; 10: 444-454.
16. Iguchi S, Toba K, Fuse I, Wada Y, Maruyama S, Takahashi M, et al. Severe cryoglobulinemia in a patient with asymptomatic hepatitis C virus infection. Intern Med 1996; 35: 712-716.
17. Grosso A, Cheung N, Veglio F, Wong TY. Similarities and differences in early retinal phenotypes in hypertension and diabetes. J Hypertens 2011; 29: 1667-1675.
18. Carraro MC, Rossetti L, Gerli GC. Prevalence of retinopathy in patients with anemia or thrombocytopenia. Eur J Haematol 2001; 67: 238-244.
19. Abe T, Nakajima A, Satoh N, Koizumi T, Sakuragi S, Ono T, et al. Clinical characteristics of hepatitis C virus-associated retinopathy. Jpn J Ophthalmol 1995; 39: 411-419.
20. Guyer DR, Tiedeman J, Yannuzzi LA, Slakter JS, Parke D, Kelley J, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111: 350-356.
21. Sharrett AR, Hubbard LD, Cooper LS, Sorlie PD, Brothers RJ, Nieto FJ, et al. Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999; 150: 263-270.
22. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010; 34: J322-326.
23. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, et al. An evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study (KULDS). J Gastroenterol Hepatol 2011.
24. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. HEPATOLOGY 2006; 43: 661-672.